Also called personalized medicine, this evolving field makes use of an individual’s genes, lifestyle, environment and other factors to identify unique disease risks and guide treatment decision-making.
Masimo's MightySat Medical is the first FDA-cleared pulse oximeter available to consumers without a prescription, which could disrupt the market for the notoriously inaccurate at-home devices.
MediView’s technologies utilize AR to provide clinicians with 3D “X-ray vision” guidance during minimally invasive procedures and surgeries, while also offering remote collaboration.
Before colonoscopy AI can progress from lab to clinic on a broad scale—and win regulatory approvals along the way—it has to show its diagnostic mettle in numerous large clinical trials conducted at multiple facilities.
Emergency physicians have a tough time identifying patients who have Crohn’s disease and truly need a CT scan to pinpoint the cause of acute abdominal distress.
Broadening clinician access to the health histories of patients’ parents and grandparents would help ward off or better treat numerous chronic illnesses common to middle-aged adults in the U.S.
Compensation for heart specialists continues to climb. What does this say about cardiology as a whole? Could private equity's rising influence bring about change? We spoke to MedAxiom CEO Jerry Blackwell, MD, MBA, a veteran cardiologist himself, to learn more.
The American College of Cardiology has shared its perspective on new CMS payment policies, highlighting revenue concerns while providing key details for cardiologists and other cardiology professionals.
As debate simmers over how best to regulate AI, experts continue to offer guidance on where to start, how to proceed and what to emphasize. A new resource models its recommendations on what its authors call the “SETO Loop.”
